S100A2 and Parkinson disease: Taken together, we proposed that the 4 signature genes (NEUROD4, GNGT1, FCN2, and S100A2) may be the essential contributors to the progression of PD-related ferroptosis, thus suggesting that targeting the diagnostic model may be an exploitation strategy for PD treatment.